Natco Pharma had reported a 11.54%  rise in its consolidated profit after tax at Rs 217.4 crore for the quarter ended December 2017. FY18 according to the company looks strong overall. Natco expects near Rs 300 crore of profits in the final quarter - this is typically a strong quarter for Natco Pharma due to flu season driving sales of the company's generic Tamiflu in the United States. However, Natco is among the top losers on high volumes today following comments from the company's management. 

Natco Pharma management is cautious about FY19, despite the launch of its generic version of multiple-sclerosis drug Copaxone. Natco in its earnings call said that is seeing significant competition in the 20 mg and 40 mg versions of the Copaxone drug - two players are launching generic versions of the drug in the United States market, which may impact Natoc's 15% market share in the 40 mg generic. For the full screener, click here.